Studies on unselected breast or ovarian cancer cohorts in different populations showed that mutation frequencies of RAD51C and RAD51D in BC patients ranged from 0.07% to 0.2% and 0.07% to 0.48%, respectively [22,26,42,43]. Here, RAD51D is linked to ovarian carcinoma.